Vor Biopharma Inc.
NASDAQVOR enters its August 18 earnings report in a genuinely charged position: short interest is massive at a third of the float, yet shorts have been quietly covering for a month while the stock climbs — and the Street just raised its target. The most telling short-side dynamic is the direction of travel, not the size. Short interest is 33.7% of the free float — a structurally high…
Snapshot as of 8 Sept 2026
VOR enters its August 18 earnings report in a genuinely charged position: short interest is massive at a third of the float, yet shorts have been quietly covering for a month while the stock climbs — and the Street…
Vor Biopharma reports Q1 2026 results on June 11 carrying one of the most conspicuous short positions in its peer group — and a significant institutional seller who has already voted with their feet. Short interest is…
VOR heads into a compressed earnings cycle with short sellers accelerating positions, a freshly reported Q1 beat, and another update due in less than a week. Short interest has been the defining story of the past…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VOR — free to start on ORTEX.
Sign up for free →Open VOR on ORTEX